RetinalGenix Technologies (RTGN) Asset Writedowns and Impairment (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Asset Writedowns and Impairment of $165375.0 for Q1 2026, little changed on a YoY basis from $165375.0 in Q1 2025, and little changed sequentially from $165375.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Asset Writedowns and Impairment data on file, last reported at $165375.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment changed 0.0% year-over-year to $165375.0; the trailing twelve-month figure through Mar 2026 stood at $661500.0 (up 1.77% YoY), and the FY2025 full-year result was $661500.0, up 1.1% from the prior year.
- Asset Writedowns and Impairment held at $165375.0 in Q1 2026, from $165375.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $452433.0 in Q4 2022 to a low of $79000.0 in Q3 2024.
- A 5-year average of $198300.2 and a median of $165375.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment jumped 2203.46% in 2022 and slumped 68.64% in 2023, its largest moves.
- Tracing RTGN's Asset Writedowns and Impairment over 5 years: stood at $452433.0 in 2022, then slumped by 68.64% to $141861.0 in 2023, then rose by 4.15% to $147751.0 in 2024, then climbed by 11.93% to $165375.0 in 2025, then changed by 0.0% to $165375.0 in 2026.
- Business Quant data shows RTGN's Asset Writedowns and Impairment at $165375.0 in Q1 2026, $165375.0 in Q4 2025, and $165375.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,375.00 |
| Mar 31, 2026 | 165,375.00 |
| Dec 31, 2025 | 165,375.00 |
| Dec 31, 2025 | 165,375.00 |
| Sep 30, 2025 | 165,375.00 |
| Sep 30, 2025 | 165,375.00 |
| Jun 30, 2025 | 165,375.00 |
| Jun 30, 2025 | 165,375.00 |
| Mar 31, 2025 | 165,375.00 |
| Mar 31, 2025 | 165,375.00 |
| Dec 31, 2024 | 147,751.00 |
| Dec 31, 2024 | 147,751.00 |
| Sep 30, 2024 | 79,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 257,899.00 |
| Jun 30, 2024 | 257,899.00 |
| Mar 31, 2024 | 169,650.00 |
| Mar 31, 2024 | 169,650.00 |
| Dec 31, 2023 | 141,861.00 |
| Dec 31, 2023 | 141,861.00 |